Ergomed completes enrollment in Ph IIb of PeproStat

Ergomed plc (LSE:ERGO) completed enrollment of >160 patients undergoing liver, soft tissue, vascular or spinal surgery in a Phase IIb trial of PeproStat to treat intraoperative surgical bleeding. The primary endpoint for the double-blind, placebo-controlled, European trial is bleed control rate. Data are expected in 4Q17...